Salute e Benessere

Precision Cardiovascular Appoints Matthew I. Mace to Board of Directors…

Matthew has over 15 years of specialised experience in both invasive and non-invasive cardiovascular technologies: Matthew has over 15 years of specialised experience in both invasive and non-invasive cardiovascular technologies: A Strategic Addition to PCV's Board "Precision Cardiovascular stands at a key moment, bridging cutting-edge research with real-world clinical impact," saidMatthew Mace. "Leveraging my experience in both implantable devices and AI-driven haemodynamic...
PR Newswire
13/02/2025

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1)…

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024REVENUE +12.4%, EBITDA (1)+12.5%, ADJUSTED NET INCOME (2)+8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS Consolidated net revenue of € 2,341.6 million for FY 2024, +12.4% or +9.2% on a like-for-like basis (3)and at constant exchange rates (CER)EBITDA (1)of € 865.8 million, +12.5%, revenue margin of 37.0% Adjusted net income (2)of € 568.9 million, +8...
Nasdaq GlobeNewswire
13/02/2025

Medical Filtration Market worth $9.35 billion by 2030 - Exclusive Report by…

230 – Tables 152 – Figures280 – Pages 230 – Tables 152 – Figures 280 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=189138733 The medical filtration market is driven by the growing prevalence of chronic diseases fueled by expansion of healthcare technologies. Medical devices such as surgical instruments and diagnostic tools need medical filters in sterilization process in order to make sure contamination free and sterile...
PR Newswire
13/02/2025

Notice to Convene the Annual General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025COPENHAGEN, Denmark; February 13, 2025 –Genmab A/S(Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed amended Remuneration Policy...
Nasdaq GlobeNewswire
13/02/2025

Vistin Pharma ASA: Key information relating to the proposed cash dividend

The Board of Directors of Vistin Pharma ASA (VISTN) will propose to distribute a cash dividend of total NOK 1.25 per share, to be paid in June, for the accounting year of 2024. The formal decision regarding the dividend will be made on the company's Annual General Meeting, which will be held on 22 May 2025. Dividend amount (per share): NOK 1.25Declared currency: NOKLast day including right: 3 June 2025Ex-date: 4 June 2025Record date: 5 June 2025Payment date (on or about): 12 June...
Nasdaq GlobeNewswire
13/02/2025

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host…

The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website athttps://ir.zymeworks.com/events-and-presentationsAbout Zymeworks Inc.Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer,...
Nasdaq GlobeNewswire
13/02/2025

First Batch of Hong Kong Elderly Residents Use Elderly Healthcare Vouchers in…

Video - https://mma.prnewswire.com/media/2619496/First_Batch_of_Hong_Kong_Elderly_Residents_Use_Elderly_Healthcare_Vouchers_in_Zhongshan.mp4 Video - https://mma.prnewswire.com/media/2619496/First_Batch_of_Hong_Kong_Elderly_Residents_Use_Elderly_Healthcare_Vouchers_in_Zhongshan.mp4 View original content: https://www.prnewswire.co.uk/news-releases/first-batch-of-hong-kong-elderly-residents-use-elderly-healthcare-vouchers-in-zhongshan-302375779.html
PR Newswire
13/02/2025

Newronika Closes €13.6 Million Series B Financing to Accelerate Development of…

Newronika's continued momentum – evidenced by recent The Michael J. Fox Foundation grant and IDE approval, and now a substantial funding round – underscores the company's central mission: to champion a paradigm shift in neuromodulation. Adaptive DBS represents the future of personalized brain stimulation, and Newronika remains dedicated to leading that evolution. Newronika's continued momentum – evidenced by recent The Michael J. Fox Foundation grant and IDE approval, and now a substantial...
PR Newswire
13/02/2025

Casino Group: Casino renews its partnership with Avia Thévenin Ducrot for a…

Casino renews its partnership withAvia Thévenin Ducrot for a further 3 years Paris, 13 February 2025 Casino and Avia Thévenin Ducrot have announced the renewal of their historic partnership for a further three years. For almost 20 years, the partnership has enabled Casino to offer customers of Avia Thévenin Ducrot stores a varied selection of products under the Casino brand and other major brands, tailored to the needs of travellers. The partnership covers 46 motorway service...
Nasdaq GlobeNewswire
13/02/2025

Implantica announces positive feedback received from U.S. FDA of the RefluxStop™…

Dr. Peter Forsell, Implantica's founder, CEO, and the inventor of RefluxStop, says, "We are thankful for FDA for their review of Module 2 and are pleased to receive their positive feedback on our submission thus far. Module 2 includes the results of the RefluxStop™ clinical study and is by far the most important module for this PMA from our perspective. The 5-year outcomes in conjunction with data reported in the literature are extremely positive and indicate that RefluxStop™ may…
PR Newswire
13/02/2025

Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results

thof February 2025Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2024.Revenue in the fourth quarter ended at MNOK 114 compared to MNOK 111 in Q4 2023. Strong operational performance resulted in more volumes available for sale in the quarter, which increased the sales volume with 11%. 2024 full year revenue ended at MNOK 430 compared to MNOK 438 last year. Sales volume increased by 4% in 2024, even with an unplanned stop...
Nasdaq GlobeNewswire
13/02/2025

Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for…

Ad hoc announcement pursuant to Art. 53 LRAGAMREE® is the first product to receive an agreed federal price in Germany for the treatment of all DMD patients 4 years and older, and independent of genetic mutation Pratteln, Switzerland, February 13, 2025 – Santhera Pharmaceuticals (SIX: SANN), a specialty pharmaceutical company focused on rare diseases, today announces an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement for...
Nasdaq GlobeNewswire
13/02/2025

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3…

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasiveE. colidiseaseNo safety signals related to the vaccine candidate were identifiedParis, February 13, 2025. A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee...
Nasdaq GlobeNewswire
13/02/2025

Sequential and AMILI Secure Prestigious $1.8M UK-Singapore Collaborative R&D…

Sequential has built a database of over 25,000 clinical skin microbiome samples and has pioneered the world's early skin microbiome at-home tests that were made commercially available in 2019. The previous recipient of an Innovate UK Smart Grant, with labs in US, Europe and Asia, Sequential is currently working with over 80 personal care and pharmaceutical companies innovating in the skin microbiome field. Sequential has built a database of over 25,000 clinical skin microbiome samples and has...
PR Newswire
13/02/2025

EU's Urban Wastewater Treatment Directive could lead to additional costs of…

ORION CORPORATIONPRESS RELEASE13 FEBRUARY 2024 at 8.00 EET EU's Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to medicine availability The EU's Urban Wastewater Treatment Directive, which entered into force on 1 January 2025, obligates the pharmaceutical, cosmetics, and hygiene products industries as manufacturers in the so-called extended producer responsibility system to cover the...
Nasdaq GlobeNewswire
13/02/2025

Ipsen delivers solid results in 2024, driven by strong performance across all…

FY 2024 total sales growth of 9.9% at CER 1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% in Neuroscience, and 7.3% in Oncology; Somatuline ®(lanreotide) sales grew by 5.6%, while all other products, excluding Somatuline, achieved double-digit sales growth at 12.2%FY 2024 core operating income of €1,109m, growing 10.8% as reported, with core operating margin of 32.6% of total...
Nasdaq GlobeNewswire
13/02/2025

Southern Star Research Applauded by Frost & Sullivan for Delivering…

Southern Star positions itself as a service provider and a trusted ally, focusing on personalized support rather than transactional relationships. This approach distinguishes it from larger CROs and pharma companies, which prioritize volume over individual client needs. The company leverages a combination of cost-effectiveness, high-quality outcomes, and reduced regulatory bureaucracy in Australia to deliver swift and effective solutions that allow biotech firms to bring their products to market…
PR Newswire
13/02/2025

Kidney Transplant Rejection Market to Observe Growth at a CAGR of 4.9% During…

Key Takeaways from the Kidney Transplant Rejection Market Report Key Takeaways from the Kidney Transplant Rejection Market Report Discover which therapies are expected to grab the major kidney transplant rejection market share @ Kidney Transplant Rejection Market Report Kidney Transplant Rejection Overview Kidney transplant rejection occurs when the recipient's immune system recognizes the donor kidney as foreign and mounts an attack against it. This immune response can be...
PR Newswire
12/02/2025

Idorsia publishes the resolutions for the upcoming bondholder meeting

Ad hoc announcement pursuant to Art. 53 LR The updated invitation to the bondholder meeting – scheduled for February 25, 2025 – sets out the terms of the resolutions to be voted uponUnaudited Financial Status as of December 31, 2024 – required for the bondholder meeting – published on the company websiteAudited Financial Statements will be published with the Full Year Financial Reporting on February 27, 2025, while the Annual Report will be postponed to March 27, 2025Allschwil,...
Nasdaq GlobeNewswire
12/02/2025

Global Medical Tourism Summit 2025: Pioneering the Future of International…

A Convergence of Global Leaders A Convergence of Global Leaders This summit will gather 200 handpicked industry leaders from theMiddle East,Europe,Asia,Africa, and the Americas. Attendees will engage in high-powered meetings and impactful sessions designed to foster partnerships and secure commercial deals. The event promises unparalleled opportunities for networking and collaboration among C-level executives, government officials, international insurers, and renowned medical...
PR Newswire
12/02/2025

Illuccix® Approved in the United Kingdom

Gary Cook, MD, Professor of Molecular Imaging at Kings College London School of Biomedical Engineering & Imaging Sciences, commented, "PSMA-PET supply shortages in the UK and Europe have escalated over the past 12 months as demand increases, which has led to delays for men in urgent need of a scan to direct clinical management. It is great news that Telix can now help address this unmet need and improve equity of access in the UK through their Illuccix imaging agent and network…
PR Newswire
12/02/2025

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Feb.12, 2025(GLOBE NEWSWIRE) --Paris, France, February 12, 2025Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of SharesOutstandingTotal number of voting...
Nasdaq GlobeNewswire
12/02/2025

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business…

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-veinFocusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel...
Nasdaq GlobeNewswire
12/02/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS 12 FEBRUARY 2025 at 21.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 11 February...
Nasdaq GlobeNewswire
12/02/2025
Altri  Comunicati